yahoo_financeOriginal article
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Trial StartEB613Positive
AI Analysis
Summary
Entera appointed Riccardo Paolo Camisasca, M.D. as Chief Medical Officer ahead of the planned Phase 3 initiation of EB613. This is a routine personnel announcement related to upcoming clinical trial activities.
Clinical Trial Data
Phase
3
Importance:3/10
Sentiment:
0.30
managementclinical_developmentPhase_3CMO_appointment
Related Companies
Read the original article
Published by yahoo_finance on August 18, 2026 12:00 PM